Skip to main content

Advertisement

Table 2 Association analysis between clinicopathologic characteristics and chemosensitivity

From: Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients

Proliferation rate (%) Gemcitabine P Oxaliplatin P 5-Fluorouracil P Nab-paclitaxel P Irinotecan P
Tumor size, cm
 < 4 65.3 ± 11.5 0.316 72.2 ± 27.9 0.814 66.5 ± 30.0 0.684 84.8 ± 28.5 0.257 71.0 ± 26.4 0.049
 ≥ 4 26.8 ± 88.6 67.3 ± 40.2 72.8 ± 21.7 35.0 ± 97.4 15.0 ± 51.9
Tumor differentiation
 Well and moderate 38.5 ± 78.2 0.699 55.0 ± 28.7 0.127 61.7 ± 24.6 0.292 35.3 ± 67.5 0.264 31.7 ± 46.8 0.449
 Poor 53.7 ± 51.2 84.5 ± 32.6 77.7 ± 25.2 84.5 ± 76.1 54.3 ± 52.7
Nerve invasion
 No 10.3 ± 72.1 0.044 74.8 ± 26.8 0.618 71.2 ± 30.2 0.848 82.7 ± 94.2 0.303 37.2 ± 56.5 0.700
 Yes 81.8 ± 24.8 64.7 ± 40.4 68.2 ± 21.9 37.2 ± 40.9 48.8 ± 44.8
Lymph node metastasis
 No 30.2 ± 85.7 0.491 55.4 ± 34.3 0.219 69.8 ± 34.1 0.989 21.4 ± 66.3 0.128 7.4 ± 38.5 0.024
 Yes 57.4 ± 46.3 80.0 ± 30.5 69.6 ± 19.7 87.4 ± 69.1 68.4 ± 40.0
TNM stage
 I–IIIA 18.3 ± 94.0 0.305 61.0 ± 36.9 0.543 64.0 ± 36.4 0.606 13.3 ± 73.6 0.122 − 7.5 ± 22.2 0.004
 IIIB–IV 60.0 ± 43.5 74.1 ± 32.7 72.5 ± 20.0 83.3 ± 65.1 68.3 ± 37.0
  1. P values were calculated by unpaired t-test (2-sided)